MDGL logo Madrigal Pharmaceuticals : MDGL

MDGL

Stock Data

$513.72

Change down

$3.67 (0.71%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Madrigal Pharmaceuticals Inc is a biopharmaceutical company in the clinical stage, primarily focused on creating treatments for non-alcoholic steatohepatitis (NASH), a liver disease. Their main product in development is resmetirom, aimed at treating NASH through a novel approach as a liver-directed thyroid hormone receptor beta agonist. Currently, resmetirom is undergoing Phase 3 clinical trials. The company operates out of West Conshohocken, Pennsylvania.

All Madrigal Pharmaceuticals Articles

8 Articles

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.